Mereo bags rights to the latest AstraZeneca castoff, shifts focus; Neos rejects buyout offer
→ London-based Mereo BioPharma has picked off an option on the rights to a Phase II drug from AstraZeneca, which has been steadily divesting itself …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
